G-15
目录号 : GC16618
An antagonist of the estrogen receptor GPER
Cas No.:1161002-05-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1,2]: | |
|
Cell lines |
Immortalized epithelial endometriotic cell line (11z) |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
10, 30, or 60 μM for 24, 48, or 72 hours |
|
Applications |
G-1 (30 μM) led to Akt phosphorylation at serine 473 within 2 hours. Pretreatment with G-15 (60 μM) prevented this phosphorylation by G-1. Treatment with 10 μM G-1 for 72 hours significantly stimulated the cells with an increase of the relative proliferation. A subsequent 72-hour treatment with 30 μM G-15 significantly reversed this stimulation. Treatment with G-15 alone led to a decrease of the relative proliferation. G-15 dose-dependently inhibited G-1–mediated calcium mobilization in SKBr3 cells with IC50 of ～185 nM. G15 inhibited the G-1–mediated activation of PI(3)K in GPR30-transfected COS7 cells. |
| Animal experiment [3]: | |
|
Animal models |
Ovariectomized female rats |
|
Dosage form |
Subcutaneous injection, 5 μg/day, 10 μg/day |
|
Application |
G-15 dose-dependently impaired DMP acquisition. G-15 specifically reduced the rate of acquisition. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Imesch P, Samartzis E P, Dedes K J, et al. Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells[J]. Fertility and sterility, 2013, 100(3): 770-776. [2]. Dennis M K, Burai R, Ramesh C, et al. In vivo effects of a GPR30 antagonist[J]. Nature chemical biology, 2009, 5(6): 421-427. [3]. Hammond R, Nelson D, Kline E, et al. Chronic treatment with a GPR30 antagonist impairs acquisition of a spatial learning task in young female rats[J]. Hormones and behavior, 2012, 62(4): 367-374. |
|
G-15 is a selective antagonist of GPR30 with Ki value of 20 nM [1].
G protein-coupled receptor 30 (GPR30) is an integral membrane protein that localizes to the endoplasmic reticulum and with high affinity for estradiol and aldosterone. GPR30 participates in multiple intracellular signaling pathways [1].
G-15 is a selective GPR30 antagonist with Ki value of 20 nM, While displayed little binding to ERα or ERβ up to 10 μM. In SKBr3 breast cancer cells that expressed only GPR30, G-1 or estrogen significantly increased intracellular calcium concentrations, while G15 inhibited the response to G-1 or estrogen with IC50 value of 185 and 190 nM respectively in a dose-dependent way. In GPR30-transfected COS7 cells, G-15 inhibited both estrogen and G-1 activation of PI3K and accumulation of PIP3 [1]. In endometriotic cells, G-1 increased cell proliferation and Akt phosphorylation, while G-15 reversed this stimulation and inhibited cell proliferation and induced Akt dephosphorylation [2].
In intact rats and ovariectomized (OVX) rats treated with estradiol, G-15 impaired acquisition of delayed matching-to-position (DMP) T-maze task with a persistent turn. The result suggested that GPR30 played an crucial role in mediating the effects of estradiol on spatial learning [3].
References:
[1]. Dennis MK, Burai R, Ramesh C, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol, 2009, 5(6): 421-427.
[2]. G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells. Fertil Steril, 2013, 100(3): 770-776.
[3]. Hammond R, Nelson D, Kline E, et al. Chronic treatment with a GPR30 antagonist impairs acquisition of a spatial learning task in young female rats. Horm Behav, 2012, 62(4): 367-374.
| Cas No. | 1161002-05-6 | SDF | |
| 化学名 | (3aR,4R,9bS)-4-(6-bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline | ||
| Canonical SMILES | BrC1=C(C=C2OCOC2=C1)[C@@H]3NC4=CC=CC=C4[C@@H]5[C@H]3CC=C5 | ||
| 分子式 | C19H16BrNO2 | 分子量 | 370.24 |
| 溶解度 | ≥ 37mg/mL in DMSO | 储存条件 | -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.701 mL | 13.5048 mL | 27.0095 mL |
| 5 mM | 0.5402 mL | 2.701 mL | 5.4019 mL |
| 10 mM | 0.2701 mL | 1.3505 mL | 2.701 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。